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adenocarcinoma: rapidly progressive visceral disease, relative
low serum PSA concentration and high response rate to
platinum-based chemotherapy (1). In the case reported, a re-
biopsy was performed for the suspicion of trans-
differentiation: local progression and no distant metastases.
The new diagnosis has allowed a more correct antiblastic
therapy. Many patients undergo for years to hormonal
therapies and often are used second-line drugs. It thus increase
the time of androgen suppression and therefore the possibility
of inducing differentiation. However, the re-biopsy is not a
routine. But due to the low complication rate, it can be widely
indicated after long course ADT. Nouri et al. studied pathways
of epithelial-to-mesenchymal transition arguing that androgen-
targeted therapy induces epithelial– mesenchymal plasticity
and neuroendocrine transdifferentiation in prostate cancer (2).
Understanding tumor cell plasticity will be important in
further defining the rational use of hormonal therapies. With
increasing recognition of cancer as a multifaceted process, the
identification and characterization of specific cell phenotypes
or the diagnosis of a trans-differentiation occurred, can help
clinicians to make more targeted therapies, an opportunity for
intervention to prolong survival in metastatic prostate cancer
patients (3).
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Introduction: Studies on the role of EGFR in non-muscle-
invasive bladder cancer (non-MIBC) are lacking. EGFR
expression has been determined mainly in tissue specimens of
MIBC and its overexpression has been associated with worse
prognosis and shorter survival. Urothelial EGFR status after
transurethral resection (TUR) of non-MIBC could indicate the
risk of recurrence and progression. We investigated the
feasibility of EGFR measurement in bladder washings of
patients undergoing intravesical adjuvant therapy for non-
MIBC and its usefulness in identifying risk subgroups.
Patients and Methods: Our prospective study included patients
after TUR of non-MIBC and healthy controls. Samples of
bladder washings were centrifuged at 4˚C for 10 minutes at
1500 rpm, washed in cold phosphate buffer saline solution and
centrifuged again obtaining a cellular pellet stored at −80˚C
until RNA extraction was performed by miRNeasy Mini Kit
(Qiagen®). A Nanodrop ND-2000 spectrophotometer was used
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Figure 1. First diagnosis (biopsy). Fragments of prostate tissue with
evidence of differentiated atypical glandular proliferation coherent
with adenocarcinoma Gleason Score 4+5=9 (grade group 5).
Nuclear morphological detail appears characterized by evident
nucleolar expression.
Figure 2. Re-biopsy after long-course ADT. Glandular population
consisting of small cells, for the most part monomorphic, with a
central nucleus and nucleus-cytoplasm ratio shifted in favor of
nucleus. Poor nucleolar evidence. Immunohistochemistry: positivity
to test for chromogranin confirmed a neuroendocrine origin of
lesion.
to check for good quality of RNA. RNA criteria to proceed
with reverse transcription to cDNA: minimum 500 ng/ml,
protein (260/280) solvents and organic compounds (260/230),
contamination ratio 1.7-2.5. The cDNA obtained from RNA
by High Capacity cDNA Reverse Transcription Kit (Life
Technologies®) was used to perform a gene expression
analysis by a real-time PCR, according to the method of the
comparative quantification (ΔΔCt) with an endogenous
control (cyclophilin). Every reaction was set in triplicate as a
further guarantee of quality. The patients were grouped for
EAU risk class and maintained in follow-up. EGFR
expressions were statistically analyzed according to EAU risk
groups and to patients’ outcomes. EGFR gene expression
values were expressed in folds of change compared to healthy
controls (EGFR=1). Results: Fifty-eight patients and 21
healthy age-matched controls were entered. An adequate
cellular pellet was obtained in 50 patients (86.2%) showing a
median EGFR expression of 2.0-fold (IQR=0.6-4.3-fold,
p=0.0004). The median level of EGFR varied considerably
among the EAU risk classes. After TUR and adjuvant
intravesical therapy, in 22 (55%) out of 40 high-risk patients,
EGFR decreased to 1.3-fold (IQR=0.9-1.5-fold), while 18
(45%) showed elevated EGFR, median=4.7-fold (IQR=4.1-
11.6-fold). At 25 months median follow-up (IQR=19.0-34.8
months), 20 (40%) patients experienced recurrence and six
(12%) progression. Among patients with and those without
EGFR gene increase, disease in nine (22.5%) and five (12.5%)
recurred and in five (12.5%) and one (2.5%) progressed,
respectively. Conclusion: In our experience EGFR expression
measurement was feasible in more than 85% of patients and
was related to EAU risk classes for recurrence and
progression, showing different behavior during intravesical
therapy. It was possible to identify a subgroup of high-risk
patients overexpressing EGFR in spite of intravesical adjuvant
therapy. EGFR evaluation in bladder washing could represent
a repeatable and useful tool to identify a subgroup of patients
at risk for progression predicted as not being responsive to
intravesical adjuvant therapy and candidates for early radical
cystectomy.
We wish to thank GSTU Foundation for data and statistical
management. 
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Introduction: Radiotherapy (RT) for the treatment of elderly
patients with prostate cancer is associated with a cancer specific
mortality risk reduction of 2.6% at 10 years, even after adjusting
for several confounders, including 12 comorbid conditions. The
aim of the present study is to evaluate the efficacy and toxicity
of high-dose, non-invasive stereotactic body radiation therapy
(SBRT) in a group of elderly patients affected by low and
intermediate risk prostate cancer. Patients and Methods:
Patients aged ≥75 years, with biopsy-confirmed prostate cancer
were enrolled. Inclusion criteria were: initial prostate-specific
antigen (PSA) ≤20 ng/ml, Gleason Score ≤7, International
Prostate Symptom Score ≤7. SBRT was performed with gantry-
based volumetric modulated arc therapy (VMAT) in its
RapidArc form and the use of flattening filter-free beams. The
treatment schedule was 35 Gy in five fractions delivered on
alternate days. Planning target volume included the prostate for
low-risk and prostate plus seminal vesicles for intermediate risk,
with a 5 mm margin of expansion in all directions. Toxicity was
recorded according to CTCAE criteria v4.0. Biochemical failure
was calculated according to the Phoenix definition. The
Expanded Prostate Cancer Index Composite questionnaire was
used to record health-related quality of life. Results: From May
2012 to April 2016, 50 patients were enrolled in the trial.
Twenty-five patients were classified in low-risk group and 25
in intermediate-risk group. The mean age was 78 (range=75-84)
years; Gleason score was 6 in 26 and 7 in 24 patients. Median
initial PSA was 6.43 (range=2.6-17) ng/ml. Median follow-up
was 26 months. Acute toxicity was mild. Rectal toxicity was
reported as grade 1 in five (10%) cases and grade 2 in one (2%)
cases; grade 1 and grade 2 genitourinary toxicity was described
in 13 (26%) and 14 (28%) patients, respectively. In the late
setting, three (6%) patients reported rectal grade 1 toxicity.
Genitourinary late effects were reported as grade 1 in 13 (26%)
patients and grade 2 in two (4%) patient. When evaluating
outcome, median nadir PSA was 0.51 ng/ml (range=0.01-3.12)
ng/ml. No biochemical relapses were observed during follow-
up and all patients were alive at the time of the analysis.
Conclusion: Gantry-based SBRT with VMAT and flattening
filter-free can be considered an effective, non-invasive and safe
approach for elderly patients affected by prostate cancer at low
and intermediate risk. Randomized trials comparing SBRT with
other approaches in this setting are necessary. 
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